Bliss GVS Pharma Ghana, a leading pharmaceutical company, has once again demonstrated its commitment to the fight against malaria in Africa through its Act for Africa campaign. This year, the company has again donated anti-malaria drugs such as LONART, P-ALAXIN, and GSUNATE worth 100,000 Ghana Cedis to the Effia Nkwanta Regional Hospital in Ghana to help combat the disease.
Malaria remains a major health challenge in Africa, with millions of people at risk of infection every year. In Ghana, malaria is a leading cause of morbidity and mortality, particularly among children under five and pregnant women. Efforts to reduce the burden of malaria have been ongoing for many years, and the donation of anti-malaria drugs by Bliss GVS Pharma is a welcome boost to these efforts.
The Effia Nkwanta Regional Hospital is a major health facility in the Western Region of Ghana, serving a large population of people. The hospital provides a range of services, including maternal and child health, emergency care, and disease management. The donation of anti-malaria drugs by Bliss GVS Pharma will help the hospital to better manage and treat cases of malaria among patients.
The Act for Africa campaign is a flagship initiative of Bliss GVS Pharma, aimed at improving access to essential medicines and healthcare services and ultimately fighting for a malaria-free continent in Africa. The campaign is guided by the belief of Bliss GVS Pharma’s managing director Mr. Gagan Sharma that every person in Africa should have access to high-quality healthcare, regardless of their social status or financial situation.
Commenting on the donation, Dr. Kwame Amponsah-Boateng, the Medical Director of Effia Nkwanta Regional Hospital, expressed his gratitude to Bliss GVS Pharma for their support in the fight against malaria. He noted that the donation of anti-malaria drugs would go a long way in helping the hospital to provide better care for patients with malaria.
The western regional representative of Bliss GVS Pharma, Mr. David, reiterated the company`s commitment to improving access to essential medicines in Africa. He noted that the Act for Africa campaign was a key part of the company’s corporate social responsibility efforts and that the company was proud to be contributing to the fight against malaria in Ghana.
In furtherance, the students of the Sekondi Nursing and Midwifery College were engaged in a health talk where resource persons equipped them with topics on personal and vaginal hygiene, malaria prevention, and spread.
The donation of anti-malaria drugs by Bliss GVS Pharma to the Effia Nkwanta Regional Hospital is a laudable initiative that will contribute significantly to the fight against malaria in Ghana. The Act for Africa campaign is a shining example of how the private sector can play a key role in improving access to healthcare in Africa.
